Xenon Pharmaceuticals Inc (XENE) is a Healthcare · Biotechnology company listed on NASDAQ. Price $40.13 (-30.03%), Market cap $5.26B, 52-week low–high $28.49 ~ $62.76.
Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the discovery, development, and delivery of therapeutics to treat patients with neurological and psychiatric disorders. Its product candidates include Azetukalner, a novel, potent Kv7 potassium channel opener which is in Phase 3 clinical development for the treatment of epilepsy, including focal onset seizures, and primary generalized tonic-clonic seizures, as well as neuropsychiatric disorders, such as major depressive disorder and bipolar depression. In addition, the company's Phase 1 Single Ascending Dose/Multiple Ascending Dose products include XEN1701 targeting the sodium channel and XEN1120 targeti
Financial statements, price targets, institutional (13F) holdings and related news for Xenon Pharmaceuticals Inc are updated in real time on BlackAll Trade.
Xenon Pharmaceuticals Inc trades at $40.13 (-30.03%). Real-time quotes and charts are available on BlackAll Trade.
Xenon Pharmaceuticals Inc has a market cap of about $5.26B.
Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the discovery, development, and delivery of therapeutics to treat patients with neurological and psychiatric di